Dec 29, 2006 by Brian LawlerWrong Dose for PanacosThe pharmaceutical company runs up against Murphy's Law.
Dec 29, 2006 by Brian LawlerThird Time's the Charm for Encysive?It seems like every other week we hear about a new delay for Encysive's lead drug Thelin.
Dec 29, 2006 by Brian LawlerSirna Decides to Take the Cash and RunShareholders vote to approve Merck's buyout offer.
Dec 29, 2006 by Brian LawlerSciClone Sees Opportunity in the Far EastPharma SciClone goes about gaining regulatory approval the opposite way from most -- through China.
Dec 29, 2006 by Brian LawlerInterMune Gets Ready to Sell SharesDrug development ain't cheap, and biotech companies have to raise money somehow.
Dec 29, 2006 by Brian LawlerLilly's Patents Stay in BloomLawsuits are just a part of doing business in the pharmaceutical industry.
Dec 29, 2006 by Brian LawlerIs Threshold on the Verge of Success?On almost any given day, the stock market's best and worst performers will be crowded with pharma and biotech stocks.
Dec 27, 2006 by Brian LawlerAlkermes' Japanese OpportunityJapan is actually the second-largest individual market for drug sales in the world.
Dec 27, 2006 by Brian LawlerBradley's Mediocre Drug ApprovalWith the FDA's approval of Bradley's Elastrin, shares were up over 10% upon approval last week.
Dec 27, 2006 by Brian LawlerTelik Falls ShortShares of another biopharma fall after disappointing clinical trial results.
Dec 26, 2006 by Brian LawlerBristol-Myers in the Giving SpiritThe pharmaceutical company knows when to fold 'em.
Dec 26, 2006 by Brian LawlerCVT Tries to Bring a Drug OverseasThe EU is an exciting market opportunity.
Dec 26, 2006 by Brian LawlerNorthfield Needs a TourniquetIts blood substitute didn't impress in a big clinical trial.
Dec 26, 2006 by Brian LawlerBarely a Ripple for New RiverThe company gets another letter from the FDA, but its ADHD drug is still on track to debut soon.
Dec 26, 2006 by Brian LawlerInterMune's Secret Drug SurpriseShares of InterMune have risen after positive trial results for one of its top drug candidates.
